Advances in pretargeting biotechnology

David A. Goodwin, Claude F. Meares

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

A major focus of current drug research is to improve drug targeting to internal target sites such as to solid tumors or specific organs. The objective of drug targeting, especially for cancer chemotherapy and radioimmunotherapy, is to enhance the effectiveness of the drug by concentrating it at the target site and minimizing its effects in nontarget sites. Although tumor targeting has been obtained with large long-circulating radiolabeled antibody molecules, normal organ activity, especially in the blood kidneys, liver, and bone marrow is a significant problem. Over the last 20 years, studies to improve the therapeutic use of antibodies have included the use of antibody fragments, chase molecules, metabolizable linkers, antibody-directed enzyme prodrugs (ADEPT), local delivery, and pretargeting. Here, we will review the most interesting recent advances in pretargeting biotechnology.

Original languageEnglish (US)
Pages (from-to)435-450
Number of pages16
JournalBiotechnology Advances
Volume19
Issue number6
DOIs
StatePublished - 2001

Keywords

  • Cancer
  • Drug targeting
  • Indium-111
  • Monoclonal antibody
  • Peptides
  • Pharmacokinetics
  • Polyethyleneglycol (PEG)
  • Pretargeting
  • Radioimmunotherapy
  • Yttrium-90

ASJC Scopus subject areas

  • Biotechnology

Fingerprint Dive into the research topics of 'Advances in pretargeting biotechnology'. Together they form a unique fingerprint.

  • Cite this